What happened
Prestige BioPharma reported consolidated results for the fiscal year ended Jun 2026: revenue of US$17.5M (+73.33% year on year), an operating loss of US$65.5M and a net loss of US$83.1M (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$17.5M |
|---|---|
| Revenue vs a year earlier | +73.33% |
| Operating profit | −US$65.5M |
| Net income | −US$83.1M |
| Period | the fiscal year ended Jun 2026 (consolidated) |
| Filed | 2026-08-14, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260814803580 → open original filing |
Source: DART. Information only, not investment advice.